Advanced in Lymphoid Hyperplasia

James Cavet

Manchester, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Lymphoid Hyperplasia
Manchester, ENG, GB 
OverviewLocationsClinical Research

Overview

James Cavet practices in Manchester, United Kingdom. Mr. Cavet is rated as an Advanced expert by MediFind in the treatment of Lymphoid Hyperplasia. His top areas of expertise are Lymphoid Hyperplasia, Castleman Disease, Multiple Myeloma, and Multicentric Castleman Disease (MCD).

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles and participated in 1 clinical trial in the study of Lymphoid Hyperplasia.

Gender
Male

Locations

Manchester, ENG M204BX, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease
ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease
Enrollment Status: Recruiting
Publish Date: November 04, 2025
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3
A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients With Relapsed or Refractory Multiple Myeloma
A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 23, 2020
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trial

9 Total Publications

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Journal: Cancer cell
Published: July 08, 2022

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cavet's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile